Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
30/06/2023 13:39
June 30 (Reuters) - Cyteir Therapeutics Inc CYT.O :
* CYTEIR THERAPEUTICS ANNOUNCES DISCONTINUATION OF CYT-0851
DEVELOPMENT PROGRAM AND PLANNED LIQUIDATION AND DISSOLUTION
* CYTEIR THERAPEUTICS-TO CONTINUE TO TREAT PATIENTS ENROLLED
IN
PHASE 1 COMBINATION STUDY WITH CAPECITABINE/GEMCITABINE BEFORE
EFFECTIVENESS OF DISSOLUTION
* CYTEIR THERAPEUTICS - BOARD INTENDS TO APPROVE PLAN OF
DISSOLUTION INCLUDING DISTRIBUTION OF REMAINING CASH TO
SHAREHOLDERS POST WIND DOWN OF OPERATIONS
* CYTEIR THERAPEUTICS - PRIOR TO WINDING DOWN OPERATIONS,
INTENDS
TO COMPLETE REGULATORY AND PATIENT OBLIGATIONS FROM ONGOING
CLINICAL TRIAL
* CYTEIR THERAPEUTICS-SEES EXISTING CAPITAL RESOURCES,
ANTICIPATED
PROCEEDS FROM SALE OF ASSETS TO ENABLE IT TO MEET OBLIGATIONS
WITH ENOUGH RESERVES
Source text for Eikon: ID:nBwlwxCQa
Further company coverage: CYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyteir Therapeutics
See all newsBrief: Cyteir Announces Timeline For Voluntarily Delisting From Nasdaq
Brief: Cyteir Therapeutics Timothy Romberger Resigned From Board & All Of Its Committees
Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile